RS62768B1 - Derivati parazola kondenzovanog prstena i postupak njihove pripreme i njihova primena u tretiranju kancera, zapaljenja i imunoloških bolesti - Google Patents

Derivati parazola kondenzovanog prstena i postupak njihove pripreme i njihova primena u tretiranju kancera, zapaljenja i imunoloških bolesti

Info

Publication number
RS62768B1
RS62768B1 RS20211556A RSP20211556A RS62768B1 RS 62768 B1 RS62768 B1 RS 62768B1 RS 20211556 A RS20211556 A RS 20211556A RS P20211556 A RSP20211556 A RS P20211556A RS 62768 B1 RS62768 B1 RS 62768B1
Authority
RS
Serbia
Prior art keywords
parazole
cancers
inflammation
condensed
preparation
Prior art date
Application number
RS20211556A
Other languages
English (en)
Inventor
Xiangyang Chen
Yucheng Pang
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of RS62768B1 publication Critical patent/RS62768B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20211556A 2016-01-29 2016-12-28 Derivati parazola kondenzovanog prstena i postupak njihove pripreme i njihova primena u tretiranju kancera, zapaljenja i imunoloških bolesti RS62768B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610066886.9A CN107021963A (zh) 2016-01-29 2016-01-29 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
PCT/CN2016/112625 WO2017128917A1 (zh) 2016-01-29 2016-12-28 吡唑稠环类衍生物、其制备方法及其在治疗癌症,炎症和免疫性疾病上的应用
EP16887788.4A EP3409672B1 (en) 2016-01-29 2016-12-28 Parazole condensed-ring derivatives and preparation method thereof and application thereof in treatment of cancers, inflammation and immune diseases

Publications (1)

Publication Number Publication Date
RS62768B1 true RS62768B1 (sr) 2022-01-31

Family

ID=59397319

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211556A RS62768B1 (sr) 2016-01-29 2016-12-28 Derivati parazola kondenzovanog prstena i postupak njihove pripreme i njihova primena u tretiranju kancera, zapaljenja i imunoloških bolesti

Country Status (20)

Country Link
US (1) US10336755B2 (sr)
EP (1) EP3409672B1 (sr)
JP (1) JP7043409B2 (sr)
KR (1) KR20180104132A (sr)
CN (2) CN107021963A (sr)
AU (1) AU2016389434B2 (sr)
CA (1) CA3012882A1 (sr)
CY (1) CY1124970T1 (sr)
DK (1) DK3409672T3 (sr)
ES (1) ES2902128T3 (sr)
HK (1) HK1256798A1 (sr)
HR (1) HRP20212020T1 (sr)
HU (1) HUE057319T2 (sr)
LT (1) LT3409672T (sr)
PL (1) PL3409672T3 (sr)
PT (1) PT3409672T (sr)
RS (1) RS62768B1 (sr)
SG (1) SG11201806438UA (sr)
SI (1) SI3409672T1 (sr)
WO (1) WO2017128917A1 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
CN110366553B (zh) * 2017-09-28 2022-04-15 上海海雁医药科技有限公司 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
WO2020151707A1 (zh) * 2019-01-22 2020-07-30 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
JP2022505053A (ja) * 2019-03-18 2022-01-14 上海海雁医薬科技有限公司 Btk阻害剤、その薬学的に許容可能な塩と結晶多形体、及びその応用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2020208222A1 (en) * 2019-04-11 2020-10-15 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as malt1 inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023535279A (ja) 2020-06-22 2023-08-17 コーセプト セラピューティクス, インコーポレイテッド 4級インダゾールグルココルチコイド受容体アンタゴニスト
WO2022048551A1 (zh) * 2020-09-01 2022-03-10 上海海雁医药科技有限公司 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
AU2022421212A1 (en) 2021-12-21 2024-07-04 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists
IL313663A (en) 2021-12-21 2024-08-01 Corcept Therapeutics Inc Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1814885A4 (en) 2004-11-23 2009-12-16 Us Therapeutics Inc Reddy NOVEL HETEROCYCLIC BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
JPWO2006126718A1 (ja) * 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
RU2008133161A (ru) 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
CA2780018C (en) 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
CA2841887A1 (en) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
CN103073508B (zh) 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
MX353548B (es) 2011-11-29 2018-01-18 Ono Pharmaceutical Co Clorhidrato derivado de purinona.
WO2013113097A1 (en) 2012-01-31 2013-08-08 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
AP2015008381A0 (en) 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
WO2014125410A1 (en) 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited N-substituted heterocyclic derivatives as kinase inhibitors
CN103113375B (zh) 2013-02-21 2017-09-15 南京勇山生物科技有限公司 一类吡唑并[3,4‑d]嘧啶类化合物及其制备方法
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX367918B (es) 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規の置換された二環式化合物
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
EA201690618A1 (ru) 2013-09-30 2016-09-30 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона

Also Published As

Publication number Publication date
CN107021963A (zh) 2017-08-08
US10336755B2 (en) 2019-07-02
HUE057319T2 (hu) 2022-04-28
HRP20212020T1 (hr) 2022-04-01
WO2017128917A8 (zh) 2017-09-14
KR20180104132A (ko) 2018-09-19
EP3409672A4 (en) 2019-07-10
ES2902128T3 (es) 2022-03-25
DK3409672T3 (da) 2022-01-10
SG11201806438UA (en) 2018-08-30
AU2016389434A1 (en) 2018-08-23
CA3012882A1 (en) 2017-08-03
NZ744870A (en) 2022-03-25
JP7043409B2 (ja) 2022-03-29
CN108602818A (zh) 2018-09-28
US20190016721A1 (en) 2019-01-17
HK1256798A1 (zh) 2019-10-04
CY1124970T1 (el) 2023-01-05
EP3409672B1 (en) 2021-12-08
CN108602818B (zh) 2021-12-21
AU2016389434B2 (en) 2021-03-11
EP3409672A1 (en) 2018-12-05
PL3409672T3 (pl) 2022-02-21
WO2017128917A1 (zh) 2017-08-03
PT3409672T (pt) 2022-01-05
JP2019503393A (ja) 2019-02-07
LT3409672T (lt) 2022-01-10
SI3409672T1 (sl) 2022-03-31

Similar Documents

Publication Publication Date Title
HK1256798A1 (zh) 吡唑稠環類衍生物、其製備方法及其在治療癌症、炎症和免疫性疾病上的應用
IL285179A (en) Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation
EP3668497A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER, INFLAMMATION, OR IMMUNE-REACTION-ASSOCIATED DISEASES
ZA201807519B (en) Liposomal preparation and methods of treatment
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
EP3312163A4 (en) DEUTERIUM-SUBSTITUTED DEHYDROPHENYLAHISTINE-LIKE COMPOUND, PREPARATION METHOD AND USE IN THE PREPARATION OF ANTITUMOR MEDICAMENT
EP3151829A4 (en) Novel sesquiterpene derivatives and their use in inflammation and cancer treatment
ZA201904966B (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
EP3565607A4 (en) FUSOGENOUS LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE FOR THE PRODUCTION OF THERAPEUTIC PROTEIN AND FOR TREATMENT PURPOSES
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
EP3873613A4 (en) 5-HALOURACIL MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
ZA201904967B (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
EP3567043A4 (en) THIENOPYRIMIDINE DERIVATIVE, PROCESS FOR PREPARATION AND APPLICATION IN THE MANUFACTURE OF ANTITUMOR DRUGS
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
EP3290034A4 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
EP3639829A4 (en) USE OF ISOVALERYLSPIRAMYCIN I, II AND / OR III IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND / OR PREVENTION OF A TUMOR, AND A MEDICINAL PRODUCT
ZA201908091B (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
EP3411122A4 (en) CANCER VACCINES AND TREATMENT METHODS THEREWITH
IL264407A (en) Administration of gzd824 and salts are accepted in the treatment of diseases
IL273790A (en) Products and methods are intended for personal cancer treatment
IL274123A (en) Co-crystals, their pharmaceutical preparations and treatment methods involving them
EP3295949A4 (en) Topical drug for treating breast cancer and preparation method thereof
EP3534918A4 (en) EXOSOMS AND USES THEREOF IN BRAIN DISEASES
PL3475310T3 (pl) Nienasycone pochodne polisacharydów, sposób ich przygotowania i zastosowanie
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING